Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Silence Therapeutics plc (SLN) reported that, as of September 30, 2026, Invus Public Equities beneficially held 7,591,233 ordinary shares (4.1%), represented by 2,530,411 ADSs, and Avicenna Life Sci Master Fund held 1,072,368 ordinary shares (0.6%), represented by 357,456 ADSs. Each ADS represents three ordinary shares.
Affiliated managers and general partners may also be deemed beneficial owners through their control relationships. Raymond Debbane may be deemed to beneficially own 8,663,601 ordinary shares (4.6%) through his control of Siren and Ulys. The ownership percentages use 186,609,072 ordinary shares outstanding as of October 15, 2026.
Key Figures
Invus Public Equities beneficial ownership:7,591,233 ordinary sharesAvicenna Fund beneficial ownership:1,072,368 ordinary sharesRaymond Debbane deemed beneficial ownership:8,663,601 ordinary shares+3 more
6 metrics
Invus Public Equities beneficial ownership7,591,233 ordinary shares4.1% of the class as of September 30, 2026
Avicenna Fund beneficial ownership1,072,368 ordinary shares0.6% of the class as of September 30, 2026
Raymond Debbane deemed beneficial ownership8,663,601 ordinary shares4.6% of the class as of September 30, 2026
Invus Public Equities ADS holdings2,530,411 ADSsRepresent the fund's 7,591,233 ordinary shares
Avicenna Fund ADS holdings357,456 ADSsRepresent the fund's 1,072,368 ordinary shares
Ordinary shares outstanding186,609,072 sharesAs of October 15, 2026; used to calculate ownership percentages
Key Terms
beneficially own, American Depositary Shares, sole voting power, sole dispositive power
4 terms
beneficially ownregulatory
"may be deemed to beneficially own the Shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
American Depositary Sharesfinancial
"aggregate of 2,530,411 American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
sole voting powerregulatory
"Sole Voting Power 7,591,233.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerregulatory
"Sole Dispositive Power 7,591,233.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many SLN shares does Raymond Debbane beneficially own?
As of September 30, 2026, Raymond Debbane may be deemed to beneficially own 8,663,601 ordinary shares, or 4.6% of the class, through his control of Siren and Ulys.
How many SLN shares did Invus Public Equities and Avicenna Fund report?
As of September 30, 2026, Invus Public Equities beneficially held 7,591,233 ordinary shares and Avicenna Life Sci Master Fund held 1,072,368 ordinary shares. Each fund's shares were represented by ADSs, with each ADS representing three ordinary shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 5)
Silence Therapeutics plc
(Name of Issuer)
Ordinary share, nominal value 0.05 GBP per share
(Title of Class of Securities)
82686Q101
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
82686Q101
1
Names of Reporting Persons
Invus Public Equities, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
BERMUDA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,591,233.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,591,233.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,591,233.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,530,411 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").
SCHEDULE 13G
CUSIP Number(s):
82686Q101
1
Names of Reporting Persons
Invus Public Equities Advisors, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,591,233.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,591,233.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,591,233.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,530,411 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").
SCHEDULE 13G
CUSIP Number(s):
82686Q101
1
Names of Reporting Persons
Invus Global Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,591,233.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,591,233.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,591,233.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,530,411 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").
SCHEDULE 13G
CUSIP Number(s):
82686Q101
1
Names of Reporting Persons
Siren, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,591,233.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,591,233.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,591,233.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.1 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,530,411 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").
SCHEDULE 13G
CUSIP Number(s):
82686Q101
1
Names of Reporting Persons
Avicenna Life Sci Master Fund LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,072,368.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,072,368.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,072,368.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 357,456 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").
SCHEDULE 13G
CUSIP Number(s):
82686Q101
1
Names of Reporting Persons
Avicenna Life Sci Master GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,072,368.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,072,368.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,072,368.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 357,456 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").
SCHEDULE 13G
CUSIP Number(s):
82686Q101
1
Names of Reporting Persons
Ulys, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,072,368.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,072,368.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,072,368.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 357,456 American Depositary Shares ("ADSs"), each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").
SCHEDULE 13G
CUSIP Number(s):
82686Q101
1
Names of Reporting Persons
Raymond Debbane
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
PANAMA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
8,663,601.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
8,663,601.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
8,663,601.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.6 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 2,530,411 American Depositary Shares ("ADSs"), and Avicenna Life Sci Master Fund LP holds an aggregate of 357,456 ADSs, each of which ADS represents three ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer").
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Silence Therapeutics plc
(b)
Address of issuer's principal executive offices:
72 Hammersmith Grove, Office 205, London, United Kingdom, W6 7AP
Item 2.
(a)
Name of person filing:
See Item 2(c) below.
(b)
Address or principal business office or, if none, residence:
See Item 2(c) below.
(c)
Citizenship:
(i) Invus Public Equities, L.P. ("Invus Public Equities")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Bermuda limited partnership
(ii) Invus Public Equities Advisors, LLC ("Invus PE Advisors")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company
(iii) Invus Global Management, LLC ("Global Management")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company
(iv) Siren, L.L.C. ("Siren")
c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company
(v) Avicenna Life Sci Master Fund LP ("Avicenna Fund")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Cayman Islands limited partnership
(vi) Avicenna Life Sci Master GP LLC ("Avicenna GP")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company
(vii) Ulys, L.L.C. ("Ulys")
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Delaware limited liability company
(viii) Mr. Raymond Debbane
750 Lexington Avenue, 30th Floor, New York, NY 10022
Citizenship: Panama
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
(d)
Title of class of securities:
Ordinary share, nominal value 0.05 GBP per share
(e)
CUSIP No.:
82686Q101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of September 30, 2026, Invus Public Equities beneficially held 7,591,233 ordinary shares, nominal value 0.05 GBP per share (the "Shares") of Silence Therapeutics plc (the "Issuer"), represented by an aggregate of 2,530,411 American Depositary Shares ("ADSs") directly held by Invus Public Equities, and Avicenna Fund beneficially held 1,072,368 Shares represented by an aggregate of 357,456 ADSs directly held by Avicenna Fund, each of which ADS represents three Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares beneficially held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares beneficially held by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own.
(b)
Percent of class:
As of September 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on 186,609,072 Shares outstanding as of October 15, 2026 based on information set forth in the Issuer's current report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See each cover page hereof.
(ii) Shared power to vote or to direct the vote:
See each cover page hereof.
(iii) Sole power to dispose or to direct the disposition of:
See each cover page hereof.
(iv) Shared power to dispose or to direct the disposition of:
See each cover page hereof.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Each of the Reporting Persons hereby makes the following certification:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Invus Public Equities, L.P.
Signature:
/s/ Raymond Debbane
Name/Title:
Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner
Date:
11/12/2026
Invus Public Equities Advisors, LLC
Signature:
/s/ Raymond Debbane
Name/Title:
Raymond Debbane, President
Date:
11/12/2026
Invus Global Management, LLC
Signature:
/s/ Raymond Debbane
Name/Title:
Raymond Debbane, President
Date:
11/12/2026
Siren, L.L.C.
Signature:
/s/ Raymond Debbane
Name/Title:
Raymond Debbane, President
Date:
11/12/2026
Avicenna Life Sci Master Fund LP
Signature:
/s/ Raymond Debbane
Name/Title:
Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner
